JP2022519007A - 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン - Google Patents
脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン Download PDFInfo
- Publication number
- JP2022519007A JP2022519007A JP2021534126A JP2021534126A JP2022519007A JP 2022519007 A JP2022519007 A JP 2022519007A JP 2021534126 A JP2021534126 A JP 2021534126A JP 2021534126 A JP2021534126 A JP 2021534126A JP 2022519007 A JP2022519007 A JP 2022519007A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- baseline
- patients
- score
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)CC(C*(CC1)C(C2)c(cc3OC(O)(O)O)c1cc3OC(O)(O)O)C2=O Chemical compound CC(C)CC(C*(CC1)C(C2)c(cc3OC(O)(O)O)c1cc3OC(O)(O)O)C2=O 0.000 description 8
- MKJIEFSOBYUXJB-UHFFFAOYSA-N CC(C)CC(CN(CCc1c2)C(C3)c1cc(OC)c2OC)C3=O Chemical compound CC(C)CC(CN(CCc1c2)C(C3)c1cc(OC)c2OC)C3=O MKJIEFSOBYUXJB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779232P | 2018-12-13 | 2018-12-13 | |
| US62/779,232 | 2018-12-13 | ||
| US201962801450P | 2019-02-05 | 2019-02-05 | |
| US62/801,450 | 2019-02-05 | ||
| PCT/US2019/066150 WO2020123900A1 (en) | 2018-12-13 | 2019-12-13 | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519007A true JP2022519007A (ja) | 2022-03-18 |
| JP2022519007A5 JP2022519007A5 (https=) | 2022-12-22 |
| JPWO2020123900A5 JPWO2020123900A5 (https=) | 2022-12-22 |
Family
ID=69173404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534126A Pending JP2022519007A (ja) | 2018-12-13 | 2019-12-13 | 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11324732B2 (https=) |
| EP (1) | EP3893876A1 (https=) |
| JP (1) | JP2022519007A (https=) |
| KR (1) | KR20210114946A (https=) |
| CN (1) | CN113395966A (https=) |
| AU (1) | AU2019395250A1 (https=) |
| BR (1) | BR112021011386A2 (https=) |
| CA (1) | CA3123393A1 (https=) |
| CL (1) | CL2021001554A1 (https=) |
| IL (1) | IL283920A (https=) |
| MX (1) | MX2021007063A (https=) |
| SG (1) | SG11202106344SA (https=) |
| TW (1) | TWI784220B (https=) |
| WO (1) | WO2020123900A1 (https=) |
| ZA (1) | ZA202104786B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI784220B (zh) * | 2018-12-13 | 2022-11-21 | 美商奧斯拜客斯製藥有限公司 | 腦性麻痺運動障礙之治療方法 |
| IL307678A (en) * | 2021-04-15 | 2023-12-01 | Neurocrine Biosciences Inc | Methods of administering certain VMAT2 inhibitors |
| JP2024514873A (ja) * | 2021-04-15 | 2024-04-03 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | デューテトラベナジンおよびｃｙｐ２ｄ６阻害剤の併用投与のための方法 |
| WO2024090922A1 (ko) | 2022-10-24 | 2024-05-02 | 주식회사 디자인셀 | 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018507248A (ja) * | 2015-03-06 | 2018-03-15 | オースペックス ファーマシューティカルズ インコーポレイテッド | 異常不随意運動障害の処置のための方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010044981A2 (en) * | 2008-09-18 | 2010-04-22 | Auspex Pharmaceutical ,Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| AU2015200243B2 (en) * | 2009-06-24 | 2016-09-29 | Egalet Ltd | Controlled release formulations |
| CA2801061A1 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| CN104684555A (zh) | 2012-09-18 | 2015-06-03 | 奥斯拜客斯制药有限公司 | 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学 |
| UA127052C2 (uk) * | 2017-03-15 | 2023-03-29 | Оспекс Фармасьютікалс, Інк. | Аналоги деутетрабеназину, їхнє отримання та застосування |
| TWI784220B (zh) * | 2018-12-13 | 2022-11-21 | 美商奧斯拜客斯製藥有限公司 | 腦性麻痺運動障礙之治療方法 |
-
2019
- 2019-12-13 TW TW108145866A patent/TWI784220B/zh active
- 2019-12-13 AU AU2019395250A patent/AU2019395250A1/en not_active Abandoned
- 2019-12-13 CA CA3123393A patent/CA3123393A1/en active Pending
- 2019-12-13 WO PCT/US2019/066150 patent/WO2020123900A1/en not_active Ceased
- 2019-12-13 BR BR112021011386-0A patent/BR112021011386A2/pt not_active Application Discontinuation
- 2019-12-13 KR KR1020217021438A patent/KR20210114946A/ko not_active Abandoned
- 2019-12-13 JP JP2021534126A patent/JP2022519007A/ja active Pending
- 2019-12-13 SG SG11202106344SA patent/SG11202106344SA/en unknown
- 2019-12-13 US US16/713,917 patent/US11324732B2/en active Active
- 2019-12-13 MX MX2021007063A patent/MX2021007063A/es unknown
- 2019-12-13 EP EP19839001.5A patent/EP3893876A1/en not_active Withdrawn
- 2019-12-13 CN CN201980089635.4A patent/CN113395966A/zh active Pending
-
2021
- 2021-06-11 CL CL2021001554A patent/CL2021001554A1/es unknown
- 2021-06-12 IL IL283920A patent/IL283920A/en unknown
- 2021-07-08 ZA ZA2021/04786A patent/ZA202104786B/en unknown
-
2022
- 2022-04-12 US US17/718,441 patent/US20220409597A1/en not_active Abandoned
-
2023
- 2023-06-28 US US18/343,197 patent/US20240082225A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018507248A (ja) * | 2015-03-06 | 2018-03-15 | オースペックス ファーマシューティカルズ インコーポレイテッド | 異常不随意運動障害の処置のための方法 |
Non-Patent Citations (5)
| Title |
|---|
| DEV. MED. CHILD NEUROL., vol. 59, JPN6024032760, 2017, pages 786 - 795, ISSN: 0005512149 * |
| MOV. DISORD., vol. 33, no. 1, JPN6024032761, June 2018 (2018-06-01), pages 92 - 93, ISSN: 0005512150 * |
| MOVEMENT DISORDERS, vol. 21, no. 11, JPN6023048261, 2006, pages 1966 - 1972, ISSN: 0005512153 * |
| NEUROLOGY, vol. Vol.82 No.10_suppl., JPN6024032762, 2014, pages 7 - 084, ISSN: 0005512151 * |
| 厚生労働省, 重篤副作用疾患別対応マニュアル ジスキネジア, JPN6024032763, 2009, pages 5 - 6, ISSN: 0005512152 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021001554A1 (es) | 2022-02-11 |
| US20240082225A1 (en) | 2024-03-14 |
| TW202034917A (zh) | 2020-10-01 |
| SG11202106344SA (en) | 2021-07-29 |
| US20220409597A1 (en) | 2022-12-29 |
| BR112021011386A2 (pt) | 2021-08-31 |
| US20200188371A1 (en) | 2020-06-18 |
| TWI784220B (zh) | 2022-11-21 |
| KR20210114946A (ko) | 2021-09-24 |
| IL283920A (en) | 2021-07-29 |
| MX2021007063A (es) | 2021-12-10 |
| ZA202104786B (en) | 2023-12-20 |
| CN113395966A (zh) | 2021-09-14 |
| EP3893876A1 (en) | 2021-10-20 |
| AU2019395250A1 (en) | 2021-07-29 |
| CA3123393A1 (en) | 2020-06-18 |
| WO2020123900A1 (en) | 2020-06-18 |
| US11324732B2 (en) | 2022-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250302851A1 (en) | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation | |
| Riddle et al. | Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial | |
| Connor et al. | Neuroleptic-related dyskinesias in children and adolescents | |
| JP2022519007A (ja) | 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン | |
| JP2026050474A (ja) | Ｎｍｄａ拮抗薬の副作用の低減 | |
| US20250000881A1 (en) | Treatment of treatment resistant depression with psilocybin | |
| JP2022514510A (ja) | うつ病の治療方法 | |
| KR20210153059A (ko) | 중수소화 덱스트로메토르판 및 퀴니딘을 사용하는 정신분열병의 음성 증상의 치료 방법 | |
| Chen et al. | Study of Feasibility and Safety of Higher‐Dose Dexmedetomidine in Special Outpatient Examination of Pediatric Ophthalmology | |
| JP2025500844A (ja) | 治療抵抗性うつ病の治療に使用するためのサイロシビン及び補助的セロトニン再取り込み阻害剤 | |
| JP2024517937A (ja) | Ｎｍｄａ受容体拮抗薬の副作用の低減 | |
| CN119654149A (zh) | 用于在治疗抑郁障碍中使用的奥法地尔的皮下施用和给药方法 | |
| EA044015B1 (ru) | Дейтетрабеназин для лечения дискинезии при церебральном параличе | |
| Ferrin et al. | Using antipsychotic medication for the treatment of schizophrenia in children and adolescents | |
| US20250375417A1 (en) | Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1) | |
| Rajab et al. | The use of chloral hydrate sedation in pediatric strabismus outpatient clinic | |
| Pearson et al. | Psychopharmacology: Issues in prescribing psychiatric medication to children and adolescents | |
| Ghaziuddin et al. | A practical guide to using ECT in minors | |
| WO2025257799A1 (en) | Methods of treating dravet syndrome | |
| Weis | Analysis of Pre-procedural Intranasal Anxiolytic Use in the Emergency Treatment of Pediatric Laceration Repair | |
| WO2025255215A1 (en) | Methods and compositions for treating sleep apnea | |
| WO2025145241A1 (en) | Treatment of gut-brain interaction disorders | |
| HK40060751A (en) | Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine | |
| Gutkovich et al. | Medication treatment of bipolar disorder in developmentally disabled children and adolescents | |
| ORLEANS | Population-level rate of SUDEP may have decreased |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221213 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231127 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231129 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240227 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240527 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241226 |